Chinese cancer genomics firm Genetron prices US IPO, targets $175.5m

Chinese cancer genomics firm Genetron prices US IPO, targets $175.5m

Photographer: Victor J. Blue/Bloomberg

Mars W. Mosqueda Jr.

17 June, 2020

CICC Capital Genetron Vivo Capital

Printed by Unregistered user on Mon, 15 Dec 2025 08:20:55 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Chinese gene testing firm Genetron files for US IPO

Venture Capital

Chinese gene testing firm Genetron snags $71m from Vivo Capital, others

Read more from Greater China

HSBC’s $13.6b buyout proposal wins Hang Seng Bank board committee nod

China Vanke’s bond payment extension rejected, raising default risk